- Provention Bio Reports Third Quarter 2019 Financial Results
- Provention Bio to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 5, 2019
- Provention Bio Announces PRV-031 (Teplizumab) Granted PRIME Designation by the European Medicines Agency
- Provention Bio Reports Top Line Results from Phase 2a PRINCE Clinical Trial with PRV-6527, an Oral CSF-1R Inhibitor, in Patients with Moderate to Severe Crohn's Disease
- Sean Doherty Joins Provention Bio Board of Directors
- Provention Bio to Present at the 2019 Cantor Global Healthcare Conference
- Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing
- Provention Bio Announces Pricing of $40 Million Public Offering of Common Stock
- Provention Bio Announces Proposed Public Offering of Common Stock
- Provention Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Provention Bio Inc (PRVB:NAQ) closed at 9.04, 494.74% above the 52 week low of 1.52 set on Jan 02, 2019.
1.52Jan 02 201922.82Jun 10 2019
Markit short selling activity
|Market cap||391.59m USD|
|EPS (TTM)||-1.02 |
Data delayed at least 15 minutes, as of Nov 20 2019 21:00 GMT.